-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 7th, Shanghai Pharmaceuticals issued an announcement stating that recently, its holding subsidiary Shanghai Shanghai Pharmaceuticals Zhongxi Pharmaceutical Co.
, Ltd.
(hereinafter referred to as “Shanghai Pharmaceuticals Zhongxi”) has received the relevant duloxetine hydrochloride enteric-coated tablets issued by the State Food and Drug Administration.
The “Notice of Approval of Supplementary Application for Drugs” (notice number: 2021B01547), the drug passed the quality and efficacy consistency evaluation of generic drugs
.
Duloxetine hydrochloride enteric-coated tablets are mainly used for the treatment of depression, originally developed as capsules, developed by Lilly, and launched in the United States in 2004
.
In January 2020, Shanghai Pharmaceuticals Zhongxi submitted an application to the State Food and Drug Administration for the consistency evaluation of the generic drug and was accepted
As of this announcement, the drug manufacturers in China only on Chinese and Western medicine Shanghai Pharmaceutical Co.
, Ltd.
and Jiangsu En Hua Pharmaceutical Co.
, Ltd.
two companies
.
According to the IQVIA database, the hospital purchase amount of duloxetine hydrochloride enteric-coated tablets in 2020 is RMB 546.
